Navigation Links
Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the 'CL Seal of Approval' a Worthless, Paid-For Advertising Gimmick
Date:1/24/2008

BOCA RATON, Fla., Jan. 24 /PRNewswire/ -- Renaissance Health Publishing, LLC is publicly disputing ConsumerLab.com, LLC's (CL) claims that they are a "leading provider of independent test results and information to help consumers and healthcare professionals evaluate health, wellness, and nutrition products," chiefly objecting to ConsumerLab.com's self-portrayal of being independent, and is warning consumers that it believes that the "CL Seal of Approval" is nothing more than an advertising gimmick.

"I simply don't believe the repeated advertising and editorial assertions of ConsumerLab.com that it is independent," says James DiGeorgia, CEO of Renaissance Health Publishing, LLC. "In my opinion, ConsumerLab.com's representation that it is an independent consumer advocate is a fraudulent, deceptive and unfair practice constructed specifically to mislead consumers."

Renaissance Health believes that consumers are being duped by ConsumerLab.com in a number of ways:

-- The very name ConsumerLab.com is misleading, as they are not a lab

-- ConsumerLab.com refuses to open their records of who has paid for (and

passed and failed) testing for the "CL Seal of Approval"

-- ConsumerLab.com issues sensationalized "name and shame" releases,

without checking for current formulations and without clearly

disclosing associations with companies that have paid for advertising

and their services

-- ConsumerLab.com is not independent, as they charge consumers for their

"impartial" reports, while at the same time accepting advertising

revenue from companies they test

"The very name of the company chosen by its owners is deceptive. They are not a lab and outsource testing to commercial labs and charge up to eight times what other commercial labs charge. If the contents of the tested product match the label you get a report and the use of their CL Seal of Approval," says DiGeorgia.
'/>"/>

SOURCE Renaissance Health Publishing, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Renaissance Health Publishing, LLC Asks Key Credibility Questions of ConsumerLab.com
2. ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Avamere Health Systems Announces New President of Signature Home Health
5. Controlling health destiny
6. The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America
7. Healthcare Workers Skeptical of Planning Process for St. Lukes
8. From Research to Practice: Healthfitness, Eastman Chemical Company Case Study Demonstrates Real-World Health Gains and Productivity Savings
9. AMA on the State of Health Care in Advance of the Presidential State of the Union Address
10. Boston Research Summit gathers 100 health care leaders on decision making
11. Accuro Healthcare Solutions, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesota's Statewide, Smoke-Free Law 2Health News:Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results 2Health News:Microsoft and HIMSS Expanding Healthcare User Group Across EMEA 2Health News:Microsoft and HIMSS Expanding Healthcare User Group Across EMEA 3Health News:Microsoft and HIMSS Expanding Healthcare User Group Across EMEA 4Health News:Hundreds to Gather for Rally in Celebration of Right to Breathe Clean Air 2Health News:Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines 2Health News:Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines 3Health News:Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines 4Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 2Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 3Health News:New ADDHERE(TM) Adhesive Tie Layer Bonds Acrylic Cap Layers to Substrates of Thermoplastic Polyolefin (TPO) in Production of Sheet for Use in Thermoforming 4
Other Medicine Technology:Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 2Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 3Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 4Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 5Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 6Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 7Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 8Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments 9Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 2Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 3Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 4Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer 5